Marinus Pharmaceuticals Inc
F:61Y
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marinus Pharmaceuticals Inc
F:61Y
|
US |
|
E
|
Energy Resources Of Australia Ltd
OTC:EGRAF
|
AU |
|
China Conch Venture Holdings Ltd
F:68C
|
CN |
|
T
|
Tandem Diabetes Care Inc
F:TD5A
|
US |
|
C
|
Clariant AG
F:CLRN
|
CH |
|
Pierce Group AB (publ)
F:959
|
SE |
|
A
|
American States Water Co
SWB:FDK
|
US |
|
AGFA Gevaert NV
F:AGE
|
BE |
Wall St Price Targets
61Y Price Targets Summary
Marinus Pharmaceuticals Inc
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 61Y's stock price target?
Not Available
61Y does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Marinus Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Revenue over the next 4 years is 36%.